AR and prostate cancer: The importance of AR reactivation during castration-resistant progression of prostate cancer has been clinically confirmed by the effective treatment of CRPC by second-generation androgen-AR axis inhibitors including abiraterone and enzalutamide (MDV3100) (de Bono et al., 2011; Scher et al., 2012).